Mihai Iliesiu, MD
Pulmonary Disease · Madison Heights, MINPI 1467682443
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,500 of the $42,561 with a category attached, or 88.1%. GSK accounts for 92.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $19,614 and has fallen 95.5% since, to $875 in 2025. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $186.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$39K
- Medical Device Business Services, Inc.$874
- AstraZeneca$457
- Regeneron Healthcare Solutions, Inc.$311
- Boehringer Ingelheim$242
- Sanofi$208
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$37,50088%
- Travel & lodging$8262%
- Food & beverage$3,9839%
- Education$2521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 101 | $39,312 |
| Medical Device Business Services, Inc. | 5 | $874 |
| AstraZeneca | 25 | $457 |
| Regeneron Healthcare Solutions, Inc. | 17 | $311 |
| Boehringer Ingelheim | 13 | $242 |
| Sanofi | 12 | $208 |
| Electromed, Inc. | 11 | $162 |
| Insmed, Inc. | 6 | $118 |
| Amgen | 2 | $117 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Mylan Specialty L.p. | 6 | $93 |
| Philips North America LLC | 3 | $83 |
| Actelion Pharmaceuticals US, Inc. | 2 | $64 |
| Novo Nordisk | 3 | $55 |
| Grifols USA, LLC | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Pulmonx Corporation | 2 | $40 |
| Genentech USA, Inc. | 1 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $26 |
| Inogen, Inc. | 1 | $22 |
| Boston Scientific | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Merck | 1 | $17 |
| Alk-abello, Inc | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$26,472
- ANORO ELLIPTA$3,718
- NA$416
How this compares
$42,561 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $91,726 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $22,310 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $19,469 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $18,653 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $10,376 |
| Spiriva RespimatTiotropium Bromide | 17 | $8,668 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $6,958 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $4,353 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,817 |
| Montelukast Sodium | 25 | $430 |
| Methylprednisolone | 16 | $130 |
| Zolpidem Tartrate | 23 | $94 |
| Azithromycin | 11 | $85 |
| Prednisone | 27 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $39,312 | $132,690162 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $457 | $26,42749 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $242 | $19,04333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Madison Heights
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
- Daniel MaxwellAlpena$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.